Safety and Effectiveness of MiniMed TM 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes
Authors' conclusion
Similar to previous studies investigating automated URLi delivery, URLi use in the MiniMed™ 780G system was safe, and glycemic outcomes were favorable for pediatric and adult participants.
Study context
- Population
- Youths and adults with T1D using MiniMed 780G advanced hybrid closed-loop; run-in ∼2 weeks with RAI (aspart or lispro) open loop or automated basal only, then 3-month study period with URLiITT population
- Participants
- 101 vs 110
- Comparison
- Advanced hybrid closed-loop (AHCL) + URLi vs predefined thresholds and baseline/run-in with RAI
- Pediatricn = 101
- Adultn = 110
- Outcome
- %TIR vs predefined thresholds
- Follow-up
- Last ∼6 weeks of study period
Methodological detailsmulticentre, 19-site
- Multicentre
- 19-site
Main finding
As reported in the abstract
- %TIR significantly greater than predefined thresholds in both pediatric and adult participants
- Intention-to-treat population
Further findings
| Outcome | Pediatric | Adult |
|---|---|---|
| Change in %TIR and %TITR vs run-in · study period | ||
| Mean %TIRΔ | 17.4% | 10.6% |
| Mean %TITRΔ | 16.0% | 11.6% |
- Change in %TIR and %TITR vs run-in — %TIR and %TITR significantly increased vs run-in
- P < 0.001 for all
A1c, pediatric cohort
- A1c unchanged in pediatric cohort
A1c, adult cohort (baseline to end of study)
- A1c reduced from 7.4 ± 0.9% to 6.9 ± 0.6%
- P < 0.001
% time above range
- % time above range significantly reduced in both groups
Recommended optimal settings (ROS)
- Use of ROS allowed more participants to achieve recommended glycemic targets
Caregiver-reported meal management
- Most caregivers agreed mealtime vs premeal URLi delivery simplified pediatric meal management
Safety
Severe hypoglycaemia and DKA · 3-month study period
- There were no severe hypoglycemia or DKA events
Original publication
Safety and Effectiveness of MiniMed TM 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes. Diabetes Technol Ther. Published 28 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →